| Methods |
RCT, 1993‐1995*, concealed allocation* |
| Participants |
39 patients randomised,
age 23‐68,
gender m/f: 22/17
country: UK
relapsed NHL (N = 38)
relapsed HD (N = 1)
stage I‐IV, biopsy proven |
| Interventions |
ECP +/‐ G‐CSF
1. CT
Etoposide 50 mg/m², po, d1‐10
Cisplatin 60 mg/m², iv, d1
Prednisolone 100 mg, po, d1‐5
2. G‐CSF 5 µg/kg/day, sc, d11‐17
3. no placebo given*
4. AB prophylaxis given |
| Outcomes |
toxicity, response rate, duration of response, survival |
| Notes |
funding: ??
This study was never published. All data presented in this review were kindly provided by Dr. Cunningham. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
